Tuberculosis 2017
DOI: 10.1183/1393003.congress-2017.pa3493
|View full text |Cite
|
Sign up to set email alerts
|

The efficiency of including the II-line drugs to the treatment regimen of isoniazid-resistant tuberculosis

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles